# China NMPA Drug Inspection - Suzhou Chunhuitang Pharmaceutical Co., Ltd. - Prepared licorice

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/suzhou-chunhuitang-pharmaceutical-co-ltd/1875ab38-fda6-405e-a02a-9293e87886b1/
Source feed: China

> China NMPA drug inspection for Suzhou Chunhuitang Pharmaceutical Co., Ltd. published April 09, 2021. Drug: Prepared licorice. On April 9, 2021, the Jiangsu Provincial Drug Administration released its first-quarter report identifying 18 batches of

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement on the Quality of Drugs in Jiangsu Province, First Quarter of 2021 (No. 6 of 2021)
- Company Name: Suzhou Chunhuitang Pharmaceutical Co., Ltd.
- Publication Date: 2021-04-09
- Drug Name: Prepared licorice
- Inspection Finding: Non-compliant item: Content determination
- Action Taken: Risk control measures such as suspending sales and use will be implemented. Investigations will be conducted into the reasons for non-compliance and rectification will be carried out. The relevant authorities will organize and carry out investigations and punishments in accordance with the law.
- Summary: On April 9, 2021, the Jiangsu Provincial Drug Administration released its first-quarter report identifying 18 batches of non-compliant pharmaceutical products. The inspection covered various manufacturers and suppliers, including Yuanhe Pharmaceutical Co., Ltd., Hubei Hepu Pharmaceutical Co., Ltd., and several traditional medicine processors such as Suzhou Chunhuitang and Jiangsu Tongji. The violations identified ranged from physical defects, such as improper appearance and excessive moisture, to critical quality issues like high impurity levels, poor content uniformity, and insufficient active ingredients. Notably, the report highlighted three instances of confirmed counterfeit products, including Sildenafil Citrate and specific herbal medicines. These inspections were conducted under the regulatory framework of the Chinese Pharmacopoeia (2015 Edition) and relevant national drug standards. In response to these findings, the provincial drug administration has mandated that all involved enterprises immediately suspend the sale and use of the affected batches. The companies are required to investigate the root causes of these failures and implement corrective actions. Furthermore, local regulatory departments have initiated legal investigations and administrative punishments against the non-compliant organizations to ensure industry integrity and protect public health.

Company: https://www.globalkeysolutions.net/companies/suzhou-chunhuitang-pharmaceutical-co-ltd/1c327431-8e4e-4449-a25f-628f2a645fb1/